Pharmaceutical Technology

SEPTEMBER 2, 2022

However, the lack of mature overall survival data for either agent means physicians will have to select therapy based on attributes other than long-term efficacy. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration Sales FDA Marketing 59

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

SEPTEMBER 13, 2022

After attempts to treat McBean’s symptoms – through cupping, applying leeches for maintenance therapy, and therapeutic phlebotomy – proved unsuccessful, his physician, Dr Thomas Watson, prescribed steel and quinine, while a sample of his urine was sent to chemical pathologist Henry Bence Jones.

Food and Drug Administration 98

Food and Drug Administration Patients Engineering Physicians 98

Pharmaceutical Representative Training

JANUARY 29, 2025

The approval of new biosimilars and the process of finding a place for them in the healthcare space will have its own set of challenges: Physician Trust: Biologics are more well-known and trusted by physicians who have been exposed to them for years. Starting in 2019, the US market was valued at $4.5

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Clarivate

AUGUST 27, 2024

In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. ablation market and would have a total global market value of $3 billion.

Marketing 52

Marketing FDA Competition Electronics 52

pharmaphorum

OCTOBER 10, 2022

Given our clinical expertise, the NHS is well placed to provide the lung check programme itself and expertise as to the key issues,” explains Dr Ley Chan, Respiratory Physician & Clinical Fellow at Royal Brompton Hospital. From an early stage, scalability was a core focus for all those involved in the development of the campaign.

Patients 98

Patients Pharma Media Training 98

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

World of DTC Marketing

DECEMBER 15, 2021

Together with the growth in wearables—projected to be worth nearly $120 billion by 2028—we are seeing growing democratization of knowledge of one’s own body, with tech enabling consumers to take a more active and regular role in their healthcare. Physicians have not bought into the hype around apps. The Economist.

Doctors 208

Doctors Medical Patients Marketing 208

World of DTC Marketing

JULY 28, 2022

Late last year, the Senate Finance Committee released draft legislation enabling Medicare negotiation for up to 10 drugs in 2025, 15 in 2026 and 2027, and 20 in 2028 and beyond. This would include drugs covered by both Medicare Part B (physician-administered drugs) and Part D (prescription medications). The secretary of the U.S.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics).

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52